AESTHETICS BIOMEDICAL® INC. ANNOUNCES KEY SCIENTIFIC FINDINGS FOR VIVACE® RADIOFREQUENCY MICRONEEDLING DEVICE
Aesthetics Biomedical® Inc. (ABM), a regenerative aesthetics medical device and topical skincare company announces new scientific findings for its radiofrequency microneedling device (RFMN), Vivace®. There has been an increasing demand for minimally-invasive procedures to address aging facial skin and other skin conditions. The energy-based radiofrequency device market continues to grow as these aesthetic patients look for effective anti-aging treatments with little associated downtime. The Vivace® is the leader in RF devices, allowing safe and efficacious aesthetic treatments by plastic surgeons, cosmetic dermatologists, and other aesthetic professionals. Clinical studies demonstrate cosmetic efficacy using RFMN devices; however, there still remains a paucity of information to explain the RF electrocoagulation mechanism on various layers of the skin, and the impact of using insulated vs. non-insulated needles. Practitioners want a more definitive understanding of how the thermal effects which occur with these devices and associated needles actually perform and can change aesthetic outcomes.
The study by Aesthetics Biomedical® Inc., a first of its kind, looked at the role of 1MHz and 2MHz amplitudes using both insulated and non-insulated needles. The 1MHz insulated needles produced an ovular shaped area of electrocoagulation and a larger surface area of controlled thermal injury as opposed to the 2MHz insulated needles, which produced a narrow columnar area of thermal injury with a smaller surface area of involvement. The histological results in the study provide practitioners with a more precise understanding of the thermal coagulation and heat dissipation effect associated with the use of different frequencies as well as the use of insulated and non-insulated needles. In summary, Vivace® treatments lead to neocollagenesis and tissue repair, including facial rejuvenation. The results of the study were published in an article titled, “An Evaluation of Electrocoagulation and Thermal Diffusion Following Radiofrequency Microneedling Using an In-Vivo Porcine Skin Model” (in press; Journal Cosmetic Dermatology)
Shaun Wootten, Director of Research & Development at Aesthetics Biomedical®, and lead author stated, “A clearer objective understanding of the electrocoagulation and thermal effects with different amplitudes and needles (insulated vs. non-insulated) is important to provide practitioners with a more precise treatment to achieve a better aesthetic outcome, including less pain and greater comfort for the patient. Additional studies are needed to further delineate the effects of RF energy on targeted and nearby tissues.”
Lawrence Rheins, Ph.D., Aesthetics Biomedical’s Chief Scientific Officer and co-author of the publication, stated, “There is a significant amount of research out there that demonstrates the safety and efficacy of radiofrequency microneedling devices. There remain gaps in our knowledge of the critical impact to the skin. The objective, histological data provides the practitioner with additional specificity regarding the accurate placement of the needles and expected efficacious aesthetic outcomes for the patient. The aesthetic industry moves quickly, and one can expect even more precise devices in the future as both the physician and patient look for more cost-effective, superior treatment for skin improvement”.
Aesthetics Biomedical® continues to focus on the company’s scientific research on the development of superior aesthetic medical devices for practitioners and patients worldwide.
ABOUT AESTHETICS BIOMEDICAL® INC:
Aesthetics Biomedical® Inc., headquartered in Phoenix, AZ, is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical’s innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network, and the aesthetic arena creating novel patient treatment experiences that benefit from ongoing research approved clinical indications for use, as well as a personalized approach designed for consumer benefit. For more information, please visit AestheticsBiomedical.com.
Marketing: Sheldon Larson, Chief Marketing Officer (Sheldon@AestheticsBiomed.com)
Press: Courtney Frappier, Senior PR Manager (CFrappier@AestheticsBiomed.com)
Disclaimer: The Vivace® Guidelines are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, medical director, or qualified health provider with any questions you may have regarding a medical condition. All suggested treatment settings are for suggested use only.